AAMU
ALLO icon

Amundi Asset Management US’s Allogene Therapeutics ALLO Stock Holding History

Amundi Asset Management US’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		$247K Hold
7,000
– – ﹤0.01% 1444
2020
Q4 		$177K Hold
7,000
– – ﹤0.01% 1415
2020
Q3 		$264K Hold
7,000
– – ﹤0.01% 1348
2020
Q2 		$300K Hold
7,000
– – ﹤0.01% 1325
2020
Q1 		$136K Buy
+7,000
New +$167K ﹤0.01% 1396

Other funds holding ALLO

TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Amundi Asset Management US's ALLO Position: Q1 2021 in Review

Amundi Asset Management US held its Allogene Therapeutics (ALLO) position steady in Q1 2021 at 7,000 shares worth $247K. The position accounts for ﹤0.01% of the portfolio, ranked #1444.

Amundi Asset Management US first reported a position in ALLO in Q1 2020 and has held it in 5 quarters since. The position peaked at $300K in Q2 2020. 169 funds tracked by Wall St. Rank hold ALLO as of Q1 2021.

  • Amundi Asset Management US held 7,000 shares of Allogene Therapeutics worth $247K as of Q1 2021.
  • Amundi Asset Management US left its Allogene Therapeutics share count unchanged in Q1 2021.
  • Allogene Therapeutics made up ﹤0.01% of Amundi Asset Management US's portfolio in Q1 2021, its #1444 holding.
  • Amundi Asset Management US first reported a position in Allogene Therapeutics in Q1 2020 and has held it in 5 quarters since.
  • Amundi Asset Management US's Allogene Therapeutics position peaked at $300K in Q2 2020.
  • 169 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q1 2021.

Based on Amundi Asset Management US's 13F filing for Q1 2021, filed 17 May 2021.